Erratum to: Subgroup analysis of the AFTER I-O study: a retrospective study on the efficacy and safety of subsequent molecular targeted therapy after immune-oncology therapy in Japanese patients with metastatic renal cell carcinoma

Affiliations

• ¹ Department of Urology, Molecular Oncology, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, Japan.
• ² Department of Urology, Nippon Medical School Hospital, Tokyo, Japan.
• ³ Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan.
• ⁴ Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
• ⁵ Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
• ⁶ Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan.
• ⁷ Bristol-Myers Squibb, Tokyo, Japan.
• ⁸ Ono Pharmaceutical Co., Ltd., Osaka, Japan.
• ⁹ Department of Urology, Keio University School of Medicine, Tokyo, Japan.